Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Imaging Steering Committee

The Clinical Imaging Steering Committee (CISC) was established in December of 2010. CISC members include representatives from National Clinical Trials Network (NCTN) Groups and other NCI sponsored networks imaging representatives, as well as other clinicians, translational scientists, biostatisticians, patient advocates, and NCI staff who support or are involved with cancer clinical imaging research.

Roles of the Committee

  • Identify and promote the "Best Science" by addressing the design and prioritization of phase 3 and large phase 2 trials focused primarily on cancer imaging;
  • Serve as a forum for the extramural imaging and oncology communities to provide strategic input to the NCI regarding its significant investment in imaging activities in clinical trials;
  • Provide valuable imaging expertise for other steering committees' evaluations of therapeutic concepts and discussions that include an imaging component.

Mission Statement

The CISC is a forum for the extramural imaging and oncology communities to provide strategic input to NCI regarding its significant investment in imaging activities in clinical trials. The CISC is charged to identify and promote the "Best Science" in clinical oncology research by addressing the design and prioritization of phase 3 and large phase 2 trials focused primarily on cancer imaging. In addition, CISC members provide valuable imaging expertise for other steering committees evaluations of therapeutic concepts and discussions that include an imaging component. The CISC is interested in facilitating the exchange of ideas among a broad range of investigators interested in cancer clinical imaging research.

Roster of Clinical Imaging Steering Committee (CISC) members

Clinical Trials

The following are clinical trials that were approved at the concept stage by the Steering Committee.

Trial ID NCT ID Trial Title
ACRIN-6702 NCT02022579 A Multi-Center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer
ACRIN-6698 NCT01564368 Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And MoLecular Analysis)
CALGB-A211201 NCT01666171 Change in Mammographic Density With Metformin Use: A Companion Study to NCIC Study MA.32

Find all NCI-sponsored clinical trials.

CCCT Contact: Steven Reeves, Ph.D.